OBJECTIVE: To determine the prevalence of infection with herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) among women with and at high risk for HIV infection, and to evaluate the effect of HAART on the recurrence of genital lesions. METHODS: We evaluated the epidemiology and clinical manifestations associated with HSV-1 and HSV-2 among 1796 HIV-infected and 476 HIV-uninfected women enrolled in a multisite cohort study. Serum antibodies to HSV-1 and HSV-2 at baseline and self-reported history of genital herpes, reports of recent genital sores and presence of genital ulcers on examination, and use of HAART regimen at each study visit were analyzed. RESULTS: Reactivity to HSV-1 only and HSV-2 only was detected in 18% and 20% of HIV-infected, and in 28% and 18% of HIV-uninfected participants respectively; 58% of HIV-infected women and 45% of HIV-uninfected women were seropositive for both HSV types. Reactivity to HSV-2 was associated with increasing age, more male sexual partners, earlier sexual debut, African-American race, Latina ethnicity, less education and lower income. HIV-uninfected women reported significantly fewer genital sores than HIV-infected women who had used HAART for at least 1 year and had optimal CD4 cell gain and viral suppression (adjusted odds ratio (OR), 0.19; 95% confidence interval (CI), 0.13-0.28). CONCLUSION: Use of HAART and subsequent immune recovery does not completely eliminate the effect of HIV infection on genital lesions among women with concurrent HSV-2 infection.
OBJECTIVE: To determine the prevalence of infection with herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) among women with and at high risk for HIV infection, and to evaluate the effect of HAART on the recurrence of genital lesions. METHODS: We evaluated the epidemiology and clinical manifestations associated with HSV-1 and HSV-2 among 1796 HIV-infected and 476 HIV-uninfectedwomen enrolled in a multisite cohort study. Serum antibodies to HSV-1 and HSV-2 at baseline and self-reported history of genital herpes, reports of recent genital sores and presence of genital ulcers on examination, and use of HAART regimen at each study visit were analyzed. RESULTS: Reactivity to HSV-1 only and HSV-2 only was detected in 18% and 20% of HIV-infected, and in 28% and 18% of HIV-uninfectedparticipants respectively; 58% of HIV-infectedwomen and 45% of HIV-uninfectedwomen were seropositive for both HSV types. Reactivity to HSV-2 was associated with increasing age, more male sexual partners, earlier sexual debut, African-American race, Latina ethnicity, less education and lower income. HIV-uninfectedwomen reported significantly fewer genital sores than HIV-infectedwomen who had used HAART for at least 1 year and had optimal CD4 cell gain and viral suppression (adjusted odds ratio (OR), 0.19; 95% confidence interval (CI), 0.13-0.28). CONCLUSION: Use of HAART and subsequent immune recovery does not completely eliminate the effect of HIV infection on genital lesions among women with concurrent HSV-2 infection.
Authors: J Daniel Kelly; Jennifer Cohen; Barbara Grimes; Susan S Philip; Sheri D Weiser; Elise D Riley Journal: J Womens Health (Larchmt) Date: 2016-05-31 Impact factor: 2.681
Authors: B Aumakhan; S J Gange; C Beyrer; C A Gaydos; H Minkoff; D J Merenstein; M H Cohen; K Anastos; R Greenblatt; M J Nowicki; T C Quinn Journal: Int J STD AIDS Date: 2011-05 Impact factor: 1.359
Authors: Susan M Graham; Linnet Masese; Ruth Gitau; Barbra A Richardson; Kishor Mandaliya; Norbert Peshu; Walter Jaoko; Jeckoniah Ndinya-Achola; Julie Overbaugh; R Scott McClelland Journal: Sex Transm Infect Date: 2010-10-27 Impact factor: 3.519
Authors: Bulbulgul Aumakhan; Charlotte A Gaydos; Thomas C Quinn; Chris Beyrer; Lorie Benning; Howard Minkoff; Daniel J Merenstein; Mardge Cohen; Ruth Greenblatt; Marek Nowicki; Kathryn Anastos; Stephen J Gange Journal: PLoS One Date: 2010-04-01 Impact factor: 3.240
Authors: Susan M Graham; Linnet Masese; Ruth Gitau; Dickson Mwakangalu; Walter Jaoko; Jeckoniah Ndinya-Achola; Kishor Mandaliya; Norbert Peshu; Jared M Baeten; R Scott McClelland Journal: J Acquir Immune Defic Syndr Date: 2009-12 Impact factor: 3.731